The Stanford Cancer Institute has been redesignated as a comprehensive cancer center by the National Cancer Institute.
The designation recognizes cancer centers across the country that meet rigorous standards for transdisciplinary, state-of-the-art research aimed at developing new and better approaches to prevent, diagnose and treat cancer.
“This is the Stanford Cancer Institute’s first renewal as an NCI-designated comprehensive cancer center,” said institute director Steven Artandi, MD, PhD. “It reflects our excellent cancer research, translation, clinical research and clinical care. It is a shared achievement and represents a team effort of our outstanding teachers, interns, nurses and staff.”
The Stanford Cancer Institute first received the designation in 2016 and is one of only 51 such centers nationally. As part of the renewal process, the institute received a five-year grant of an estimated $21 million from the NCI.
“Despite the challenges of the COVID-19 pandemic, cancer research and care has thrived at Stanford Medicine,” said Lloyd Minor, MD, dean of Stanford University School of Medicine. “The Stanford Cancer Institute has never been as strong or better positioned to make an impact in the cancer field as it is today. This funding will build on our existing institutional commitment and enhance the SCI’s ability to execute on its strategic cancer plan.”
The grant supports the Institute’s efforts to translate breakthroughs in cancer research into clinical care; increasing access to cancer care and clinical trials for underprivileged groups in the Bay Area; and ensure cancer research benefits all segments of the population, including minorities, women, children and older adults, through the efforts of the institute’s new Office of Cancer Health Equity and Community Engagement.
It will also support team science through strategic faculty recruitment and pilot projects that foster collaboration across disciplines, and strengthen and enhance the development of shared resources for the benefit of the entire Stanford research community.
“The Stanford Cancer Institute plays a critical role in our vision to increase patients’ access to personalized, advanced cancer care, based on the latest biomedical research,” said David Entwistle, president and CEO of Stanford Health Care. “The NCI’s repurposing as a comprehensive cancer center reaffirms the Institute’s steadfast commitment to the highest level of research and clinical care serving our patients and our community.”
Paul King, president and CEO of Stanford Children’s Health, said: “Through state-of-the-art treatments and exceptional patient care, the Stanford Cancer Institute is critical to advancing the health and healing of children in our community and beyond. With this renewal of its comprehensive designation as a cancer center, the institute will continue to advance our clinical and research missions.”
Since 2015, the Stanford Cancer Institute has recruited key faculty members who are national leaders in cancer drug discovery, population science, cancer health inequality, and pediatric oncology; made significant investments in genomics and precision oncology, immuno-oncology, cancer cell therapy, drug discovery and cancer therapies; and saw a marked increase in patient participation in clinical trials, in NCI funding, and in high-impact publications co-authored with the researchers.